Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Drug Profile

Testosterone intranasal (low-dose) - Acerus Pharmaceuticals

Alternative Names: MPP-14; Noseafix; TBS-2; Tefina

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals; Trimel Biopharma
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Female sexual dysfunction

Highest Development Phases

  • Phase II Anorgasmia
  • No development reported Decreased libido

Most Recent Events

  • 05 Apr 2018 Testosterone intranasal (low-dose) - Acerus Pharmaceuticals is available for licensing as of 05 Apr 2018. www.aceruspharma.com
  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 30 Jun 2015 Testosterone intranasal (low-dose) is still in phase II trials for Anorgasmia in USA, Australia and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top